TCRT Stock - Alaunos Therapeutics, Inc.
Unlock GoAI Insights for TCRT
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $10,000 | $5,000 | $2.92M | $398,000 | N/A |
| Gross Profit | $10,000 | $-4,798,000 | $2.92M | $398,000 | $-1,128,000 |
| Gross Margin | 100.0% | -95960.0% | 100.0% | 100.0% | N/A |
| Operating Income | $-4,812,000 | $-34,267,000 | $-35,105,000 | $-77,549,000 | $-80,361,000 |
| Net Income | $-4,679,000 | $-35,140,000 | $-37,730,000 | $-78,751,000 | $-79,976,000 |
| Net Margin | -46790.0% | -702800.0% | -1291.2% | -19786.7% | N/A |
| EPS | $-2.92 | $-21.97 | $-25.97 | $-53.80 | $-56.42 |
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers; hunTR, a human neoantigen T-cell receptor platform; and mbIL-15 to treat solid tumors. Alaunos Therapeutics, Inc. has a license agreement with PGEN Therapeutics, Inc.; research and development agreement with The University of Texas MD Anderson Cancer Center; and a patent license agreement, and research and development agreement with the National Cancer Institute. The company was formerly known as ZIOPHARM Oncology, Inc. and changed its name to Alaunos Therapeutics, Inc. in January 2022. Alaunos Therapeutics, Inc. is headquartered in Houston, Texas.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| October 4th 2022 | Wells Fargo | Resumed | Overweight | $3 |
Earnings History & Surprises
TCRTEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 13, 2026 | — | — | — | — |
Q4 2025 | Nov 14, 2025 | $-4.90 | $-0.55 | +88.8% | ✓ BEAT |
Q3 2025 | Aug 14, 2025 | $-5.33 | $-0.63 | +88.2% | ✓ BEAT |
Q2 2025 | May 15, 2025 | $-6.44 | $-0.67 | +89.6% | ✓ BEAT |
Q1 2025 | Mar 31, 2025 | $-4.50 | $-0.46 | +89.8% | ✓ BEAT |
Q4 2024 | Nov 14, 2024 | $-4.50 | $-0.70 | +84.4% | ✓ BEAT |
Q3 2024 | Aug 14, 2024 | $-4.50 | $-0.71 | +84.2% | ✓ BEAT |
Q2 2024 | May 15, 2024 | $-4.50 | $-1.10 | +75.6% | ✓ BEAT |
Q2 2024 | Apr 2, 2024 | $-0.45 | $-0.49 | -8.9% | ✗ MISS |
Q4 2023 | Nov 14, 2023 | $-4.50 | $-6.00 | -33.3% | ✗ MISS |
Q3 2023 | Aug 14, 2023 | $-6.00 | $-6.00 | 0.0% | = MET |
Q2 2023 | May 10, 2023 | $-6.00 | $-6.00 | 0.0% | = MET |
Q1 2023 | Mar 7, 2023 | $-13.49 | $-6.00 | +55.5% | ✓ BEAT |
Q4 2022 | Nov 14, 2022 | $-17.99 | $-6.00 | +66.6% | ✓ BEAT |
Q3 2022 | Aug 15, 2022 | $-16.49 | $-7.50 | +54.5% | ✓ BEAT |
Q2 2022 | May 16, 2022 | $-13.49 | $-7.50 | +44.4% | ✓ BEAT |
Q1 2022 | Mar 30, 2022 | $-13.49 | $-7.50 | +44.4% | ✓ BEAT |
Q4 2021 | Nov 8, 2021 | $-0.13 | $-0.11 | +15.4% | ✓ BEAT |
Q3 2021 | Aug 13, 2021 | $-0.12 | $-0.11 | +8.3% | ✓ BEAT |
Q2 2021 | May 6, 2021 | $-0.10 | $-0.10 | 0.0% | = MET |
Frequently Asked Questions about TCRT
What is TCRT's current stock price?
What is the analyst price target for TCRT?
What sector is Alaunos Therapeutics, Inc. in?
What is TCRT's market cap?
Does TCRT pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to TCRT for comparison